ArticleJournal of molecular medicine (Berlin, Germany)2026
Inhibition of ELK1 promotes osteogenic differentiation of periodontal ligament stem cells by reducing ubiquitin-mediated degradation of DLX2.
Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Periodontal ligament stem cells (PDLSCs) are promising for oral and maxillofacial bone regeneration, but the mechanisms regulating their osteogenic differentiation remain unclear. This study aimed to determine the role of DLX2 and its regulation by ELK1, STUB1, and USP11 in PDLSCs. PDLSCs were genetically manipulated using lentiviral vectors. Osteogenesis was assessed by ALP and Alizarin Red S staining and expression of osteogenic markers. Protein interactions and ubiquitination were examined by co-immunoprecipitation and cycloheximide-chase assays. ELK1-dependent STUB1 transcription was verified by ChIP and luciferase reporter assays. A mouse mandibular defect model provided in vivo validation. DLX2 overexpression increased ALP activity, mineralization, and RUNX2, OSX, and OCN expression, whereas DLX2 silencing had opposite effects. DLX2-overexpressing PDLSCs enhanced bone formation in mandibular defects. STUB1 interacted with DLX2 and promoted its ubiquitination and degradation, whereas STUB1 knockdown stabilized DLX2. USP11 bound DLX2, reduced its ubiquitination, and stabilized the protein. ELK1 bound and activated the STUB1 promoter. ELK1 silencing reduced STUB1 expression, increased DLX2 and osteogenic markers, and enhanced bone formation; STUB1 overexpression partially reversed these effects. ELK1 suppresses PDLSC osteogenesis through STUB1-mediated DLX2 degradation, while USP11 stabilizes DLX2. This ELK1-STUB1-DLX2 axis may be a potential target for craniofacial bone regeneration.
Indexed as
Identifiers
42909606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.